Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 254 entries
View as:

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Phase: N/A Priority: Normal
NCT ID: NCT00089583 Org: User:
Start: 07/31/04 End: 07/31/13 Due: 07/31/14

A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01762995 Org: User:
Start: 12/31/12 End: 03/31/13 Due: 03/31/14

Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

Phase: N/A Priority: Normal
NCT ID: NCT01056874 Org: User:
Start: 03/31/10 End: 04/30/10 Due: 04/30/11

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04484337 Org: User:
Start: 07/31/20 End: 05/05/23 Due: 05/05/24

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

Phase: N/A Priority: Normal
NCT ID: NCT05896761 Org: User:
Start: 10/28/21 End: 08/23/22 Due: 08/23/23

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

Phase: N/A Priority: Normal
NCT ID: NCT01498861 Org: User:
Start: 12/31/11 End: 03/31/12 Due: 03/31/13

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

Phase: N/A Priority: Normal
NCT ID: NCT02625207 Org: User:
Start: 11/06/15 End: 03/26/16 Due: 03/26/17

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

Phase: N/A Priority: Normal
NCT ID: NCT05514509 Org: User:
Start: 10/28/22 End: 08/29/25 Due: 08/29/26

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02539576 Org: User:
Start: 10/31/15 End: 11/30/15 Due: 11/30/16

A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00666705 Org: User:
Start: 02/29/08 End: 03/31/08 Due: 03/31/09

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

Phase: N/A Priority: Normal
NCT ID: NCT04399551 Org: User:
Start: 09/28/20 End: 03/13/23 Due: 03/13/24

Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

Phase: N/A Priority: Normal
NCT ID: NCT03682848 Org: User:
Start: 04/09/19 End: 09/30/24 Due: 09/30/25

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02059031 Org: User:
Start: 02/28/14 End: 06/30/14 Due: 06/30/15

An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc

Phase: N/A Priority: Normal
NCT ID: NCT01776996 Org: User:
Start: - End: - Due: -

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Phase: N/A Priority: Normal
NCT ID: NCT01366547 Org: User:
Start: 06/30/11 End: 07/31/11 Due: 07/31/12

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

Phase: N/A Priority: Normal
NCT ID: NCT02429791 Org: User:
Start: 04/14/15 End: 05/30/23 Due: 05/30/24

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

Phase: N/A Priority: Normal
NCT ID: NCT02674581 Org: User:
Start: 02/26/16 End: 05/24/16 Due: 05/24/17

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04263142 Org: User:
Start: 01/27/20 End: 03/24/20 Due: 03/24/21

Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

Phase: N/A Priority: Normal
NCT ID: NCT02805556 Org: User:
Start: 03/15/16 End: 05/05/16 Due: 05/05/17

Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia

Phase: N/A Priority: Normal
NCT ID: NCT01275625 Org: User:
Start: 06/30/11 End: 07/31/13 Due: 07/31/14

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

Phase: N/A Priority: Normal
NCT ID: NCT02715479 Org: User:
Start: 04/30/16 End: 05/31/16 Due: 05/31/17

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04371380 Org: User:
Start: 09/16/20 End: 12/26/21 Due: 12/26/22

GSK1349572 Drug Interaction Study With Efavirenz

Phase: N/A Priority: Normal
NCT ID: NCT01098526 Org: User:
Start: 03/16/10 End: 05/26/10 Due: 05/26/11

Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

Phase: N/A Priority: Normal
NCT ID: NCT00850395 Org: User:
Start: 07/31/09 End: 10/31/11 Due: 10/31/12

Dolutegravir Expanded Access Study

Phase: N/A Priority: Normal
NCT ID: NCT01536873 Org: User:
Start: 06/14/12 End: 09/23/16 Due: 09/23/17